Current State of Biomarkers in Bipolar Disorder

Current Psychiatry Reports

Volumn 16, Issue 12, 2014, Pages

  Scola, Gustavo ^a,b   Andreazza, Ana Cristina ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomarkers; Bipolar disorder; Inflammation; Neuroimaging; Oxidative stress; Trophic factor

Indexed keywords

4 HYDROXYNONENAL; 8 ISOPROSTANE; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CATECHOL METHYLTRANSFERASE; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LITHIUM; MALONALDEHYDE; MICRORNA; NEUROTROPHIN; NITRIC OXIDE; PROGRANULIN; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; URACIL; VASCULOTROPIN;

BIPOLAR DISORDER; CACNA1C GENE; CATECHOLAMINE SYNTHESIS; CELL DIFFERENTIATION; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA POLYMORPHISM; DNA STRUCTURE; DOWN REGULATION; DTNA GENE; EARLY DIAGNOSIS; EMOTIONALITY; ENCEPHALITIS; ENERGY YIELD; FOXP1 GENE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; GENETIC ASSOCIATION; GNG2 GENE; HIGH RISK PATIENT; HUMAN; ITPR2 GENE; LIPID PEROXIDATION; LSAMP GENE; MASS FRAGMENTOGRAPHY; NCOA2 GENE; NEUROIMAGING; NEUROPROTECTION; NONHUMAN; NPAS3 GENE; NTRK3 GENE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTON NUCLEAR MAGNETIC RESONANCE; RESPIRATORY CHAIN; REVIEW; REWARD; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; GENETICS; IMMUNOLOGY; METABOLISM;

BIOLOGICAL MARKERS; BIPOLAR DISORDER; HUMANS;

EID: 84912554773     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-014-0514-4     Document Type: Review

References (79)

1. Frey BN, Andreazza AC, Houenou J, et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatr. 2013;47(4):321–32. This positional report from the ISBD-BIONET explores the most significant data regarding the search and development of potential biomarkers.
2. Brown NC, Andreazza AC, Young LT. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 2014;218(1–2):61–8. This meta-analysis supports the involvment of oxidative stress in the pathophysiology of bipolar disorder, especially to lipids, DNA and RNA.
3. Andreazza AC, Young LT. The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. Int J Neuropsychopharmacol. 2014;17(7):1039–52.
4. Kittel-Schneider S, Weigl J, Volkert J, et al. Further evidence for plasma progranulin as a biomarker in bipolar disorder. J Affect Disord. 2014;157:87–91.
5. Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 4th ed. Oxford: Clarendon; 2007.
6. Adam-Vizi V, Starkov AA. Calcium and mitochondrial reactive oxygen species generation: how to read the facts. J Alzheimers Dis. 2010;20 Suppl 2:S413–26.
7. Scola G, Kim HK, Young LT, et al. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol Psychiatry. 2013;73:e4–5. This report discusses and emphasises that alterations to the mitochondrial electron transport chain may have an important role in the etiology of bipolar disorder.
8. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997;82:291–5.
9. Xing M. Oxidative stress: a new risk factor for thyroid cancer. Endocr Relat Cancer. 2012;19:C7–C11.
10. Hovatta I, Juhila J, Donner J. Oxidative stress in anxiety and comorbid disorders. Neurosci Res. 2010;68:261–75.
11. Wang JF, Shao L, Sun X, et al. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 2009;11:523–9.
12. Che Y, Wang JF, Shao L, et al. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci. 2010;35:296–302.
13. Andreazza AC, Shao L, Wang JF, et al. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry. 2010;67:360–8. In this post-translational study important findings were found to the mitochondrial complex I and identifies potential therapeutic targets for the treatment of bipolar disorder.
14. Andreazza AC, Wang JF, Salmasi F, et al. Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J Neurochem. 2013;127(4):552–61.
15. Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett. 2007;421:33–6.
16. Andreazza AC, Kauer-Sant’anna M, Frey BN, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 2008;111:135–44.
17. Andreazza AC, Kapczinski F, Kauer-Sant’Anna M, et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 2009;34:263–71.
18. Kapczinski F, Dal-Pizzol F, Teixeira AL, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res. 2011;45:156–61.
19. Kim HK, Andreazza AC, Yeung PY, et al. Oxidation and nitration in dopaminergic areas of the prefrontal cortex from patients with bipolar disorder and schizophrenia. J Psychiatry Neurosci. 2014;39:130155.
20. Aydemir O, Cubukçuo Lu Z, Erdin S, et al. Oxidative stress markers, cognitive functions, and psychosocial functioning in bipolar disorder: an empirical cross-sectional study. Rev Bras Psiquiatr. 2014.
21. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609–23.
22. Halliwell B. Biochemistry of oxidative stress. Biochem Soc Trans. 2007;35:1147–50.
23. Banerjee U, Dasgupta A, Rout JK, et al. Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:56–61.
24. Versace A, Andreazza AC, Young LT, et al. Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Mol Psychiatry. 2013;19(2):200–8. This is one of the first reports regarding the correlation between lipid peroxidation and alterations to white matter.
25. Gergerlioglu HS, Savas HA, Bulbul F, et al. Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:697–702.
26. Selek S, Savas HA, Gergerlioglu HS, et al. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord. 2008;107:89–94.
27. Ozcan ME, Gulec M, Ozerol E, et al. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol. 2004;19:89–95.
28. Abdolmaleky HM, Cheng KH, Faraone SV, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet. 2006;15:3132–45.
29. D’Addario C, Dell’Osso B, Palazzo MC, et al. Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology. 2012;37:1647–55.
30. Huzayyin AA, Andreazza AC, Turecki G, et al. Decreased global methylation in patients with bipolar disorder who respond to lithium. Int J Neuropsychopharmacol. 2014;17:561–9.
31. Scola G, Kim HK, Young LT, et al. Lithium reduces the effects of rotenone-induced complex I dysfunction on DNA methylation and hydroxymethylation in rat cortical primary neurons. Psychopharmacology (Berl). 2014.
32. Soeiro-de-Souza MG, Andreazza AC, Carvalho AF, et al. Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol. 2013;16:1505–12.
33. Mufson EJ, Kroin JS, Sendera TJ, et al. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol. 1999;57:451–84.
34. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol. 2000;10:381–91.
35. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736.
36. Cunha AB, Frey BN, Andreazza AC, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett. 2006;398:215–9.
37. Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett. 2009;466:139–43.
38. Fernandes BS, Gama CS, Ceresér KM, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45:995–1004.
39. Rosa AR, Singh N, Whitaker E, et al. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor [BDNF] levels. Psychol Med. 2014. 1–10.
40. Södersten K, Pålsson E, Ishima T, et al. Abnormality in serum levels of mature brain-derived neurotrophic factor [BDNF] and its precursor proBDNF in mood-stabilized patients with bipolar disorder: a study of two independent cohorts. J Affect Disord. 2014;160:1–9. This study suggests that alterations in the conversion of pro to mature BDNF may be associated with the pathophysiology of bipolar disorder.
41. Squassina A, Costa M, Congiu D, et al. Insulin-like growth factor 1 [IGF-1] expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacol Res. 2013;73:1–7.
42. Kikuchi K, Iga J, Tayoshi S, et al. Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and patients with bipolar disorder. Hum Psychopharmacol. 2011;26:358–63.
43. Palomino A, González-Pinto A, Martinez-Cengotitabengoa M, et al. Relationship between negative symptoms and plasma levels of insulin-like growth factor 1 in first-episode schizophrenia and bipolar disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;44:29–33.
44. Pereira AC, McQuillin A, Puri V, et al. Genetic association and sequencing of the insulin-like growth factor 1 gene in bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet. 2011;156:177–87.
45. Fournier NM, Lee B, Banasr M, et al. Vascular endothelial growth factor regulates adult hippocampal cell proliferation through MEK/ERK- and PI3K/Akt-dependent signaling. Neuropharmacology. 2012;63:642–52.
46. Nowacka MM, Obuchowicz E. Vascular endothelial growth factor [VEGF] and its role in the central nervous system: a new element in the neurotrophic hypothesis of antidepressant drug action. Neuropeptides. 2012;46:1–10.
47. Takebayashi M, Hashimoto R, Hisaoka K, et al. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J Neural Transm. 2010;117:1119–22.
48. Iga J, Ueno S, Yamauchi K, et al. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:658–63.
49. Isung J, Mobarrez F, Nordström P, et al. Low plasma vascular endothelial growth factor [VEGF] associated with completed suicide. World J Biol Psychiatry. 2012;13:468–73.
50. Lee BH, Kim YK. Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. J Affect Disord. 2012;136:181–4.
51. Shibata T, Yamagata H, Uchida S, et al. The alteration of hypoxia inducible factor-1 [HIF-1] and its target genes in mood disorder patients. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:222–9.
52. Goldstein BI, Fagiolini A, Houck P, et al. Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord. 2009;11:657–62.
53. Leboyer M, Soreca I, Scott J, et al. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 2012;141:1–10.
54. Stuart MJ, Baune BT. Chemokines and chemokine receptors in mood disorders, schizophrenia, and cognitive impairment: a systematic review of biomarker studies. Neurosci Biobehav Rev. 2014;42C:93–115.
55. Munkholm K, Braüner JV, Kessing LV, et al. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013;47:1119–33.
56. Rao JS, Harry GJ, Rapoport SI, et al. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry. 2010;15:384–92.
57. Brietzke E, Stabellini R, Grassis-Oliveira R, et al. Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics. CNS Spectr. 2011;16:157–68.
58. Hope S, Dieset I, Agartz I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res. 2011;45(12):1608–16.
59. Drexhage RC, Knijff EM, Padmos RC, et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother. 2010;10:59–76.
60. Herberth M, Koethe D, Levin Y, et al. Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics. 2011;11:94–105.
61. Goldstein BI, Collinger KA, Lotrich F, et al. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Child Adolesc Psychopharmacol. 2011;21:479–84. This report addresses novel evidence regarding biomarkers among adolescents with bipolar disorder.
62. Zell R, Geck P, Werdan K, et al. TNF-alpha and IL-1 alpha inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Mol Cell Biochem. 1997;177:61–7.
63. Behrens MM, Ali SS, Dugan LL. Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. J Neurosci. 2008;28:13957–66.
64. Alsaif M, Guest PC, Schwarz E, et al. Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection. Proteomics Clin Appl. 2012;6:297–303.
65. Zheng P, Chen JJ, Huang T, et al. A novel urinary metabolite signature for diagnosing major depressive disorder. J Proteome Res. 2013;12:5904–11.
66. Zheng P, Dong Wei. YD, Yao G, et al. Novel urinary biomarkers for diagnosing bipolar disorder. Metabolomics. Springer; 2013.
67. Xu XJ, Zheng P, Ren GP, et al. 2,4-Dihydroxypyrimidine is a potential urinary metabolite biomarker for diagnosing bipolar disorder. Mol Biosyst. 2014;10:813–9.
68. Hahn C, Lim HK, Lee CU. Neuroimaging findings in late-onset schizophrenia and bipolar disorder. J Geriatr Psychiatry Neurol. 2014;27:56–62.
69. Huang SH, Tsai SY, Hsu JL, et al. Volumetric reduction in various cortical regions of elderly patients with early-onset and late-onset mania. Int Psychogeriatr. 2011;23:149–54.
70. Haller S, Xekardaki A, Delaloye C, et al. Combined analysis of grey matter voxel-based morphometry and white matter tract-based spatial statistics in late-life bipolar disorder. J Psychiatry Neurosci. 2011;36:391–401.
71. Phillips ML, Swartz HA. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am J Psychiatry. 2014;171(8):829–43. This positional report discusses the limitations of neuroimaging studies and suggests new approaches to guide diagnosis and treatment for patients with bipolar disorder.
72. Nurnberger JI, Koller DL, Jung J, et al. Identification of pathways for bipolar disorder: a meta-analysis. JAMA Psychiatry. 2014;71:657–64.
73. Group PGCBDW. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet. 2011;43(10):977–83.
74. Fiorentino A, O’Brien NL, Locke DP, et al. Analysis of ANK3 and CACNA1C variants identified in bipolar disorder whole genome sequence data. Bipolar Disord. 2014;16:583–91.
75. Erk S, Meyer-Lindenberg A, Linden DE, et al. Replication of brain function effects of a genome-wide supported psychiatric risk variant in the CACNA1C gene and new multi-locus effects. Neuroimage. 2014;94:147–54.
76. Rong H, Liu TB, Yang KJ, et al. MicroRNA-134 plasma levels before and after treatment for bipolar mania. J Psychiatr Res. 2011;45:92–5.
77. Nurnberger JI, McInnis M, Reich W, et al. A high-risk study of bipolar disorder. Childhood clinical phenotypes as precursors of major mood disorders. Arch Gen Psychiatry. 2011;68:1012–20.
78. Duffy A, Alda M, Hajek T, et al. Early stages in the development of bipolar disorder. J Affect Disord. 2010;121:127–35.
79. Rasic D, Hajek T, Alda M, et al. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk studies. Schizophr Bull. 2014;40:28–38.